Explanations for the high potency of HPV prophylactic vaccines.

about

New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue.Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination

P2860

Q55668744-4629F287-B22B-4EDD-97FD-49A778668DA4 Q56355788-4B5DD041-4A6E-42EE-986A-52565A2DA60F

P2860

Explanations for the high potency of HPV prophylactic vaccines.

Item

http://www.wikidata.org/entity/Q47554977

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Explanations for the high potency of HPV prophylactic vaccines.

@en

Explanations for the high potency of HPV prophylactic vaccines.

@nl

type

Item

label

Explanations for the high potency of HPV prophylactic vaccines.

@en

Explanations for the high potency of HPV prophylactic vaccines.

@nl

altLabel

Explanations for the high potency of HPV prophylactic vaccines

@en

prefLabel

Explanations for the high potency of HPV prophylactic vaccines.

@en

Explanations for the high potency of HPV prophylactic vaccines.

@nl

P1476

Explanations for the high potency of HPV prophylactic vaccines.

@en

P2093

Doug Lowy

http://www.w3.org/2001/XMLSchema#string

John Schiller

http://www.w3.org/2001/XMLSchema#string

P2860

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

Predominant autoantibody production by early human B cell precursors

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Why HIV virions have low numbers of envelope spikes: implications for vaccine development.

In vivo mechanisms of vaccine-induced protection against HPV infection.

Molecular underpinning of B-cell anergy.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Responsiveness of B cells is regulated by the hinge region of IgD.

P304

4768-4773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2017.12.079

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

32 Pt A

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29325819

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

molecular medicine

P932

6035892

http://www.w3.org/2001/XMLSchema#string

Explanations for the high potency of HPV prophylactic vaccines.

about

P2860

P2860

Explanations for the high potency of HPV prophylactic vaccines.

description

name

type

label

altLabel

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932